Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Biomarkers in Tissue Samples From Patients With Metastatic Colon Cancer

This study has been withdrawn prior to enrollment.
Information provided by:
Georgetown University Identifier:
First received: November 12, 2009
Last updated: March 23, 2011
Last verified: March 2011

November 12, 2009
March 23, 2011
January 2000
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT01012804 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Study of Biomarkers in Tissue Samples From Patients With Metastatic Colon Cancer
Assessment of Variation of PKA and Other Molecular Markers in Patients Undergoing Resection of Colon Cancer Metastases

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.

PURPOSE: This research study is looking at biomarkers in tissue samples from patients with metastatic colon cancer.


  • Determine the effect of surgical resection, in terms of physiological stress, on levels of tumor markers such as protein kinase A (PKA) expression in patients with metastatic colon cancer.
  • Estimate variation among patients of baseline tumor markers in tumor tissue and sera.
  • Correlate markers in tumor tissues with that in sera in these patients.
  • Establish a tissue bank of these specimens for future studies.

OUTLINE: Biopsy and surgical specimens are obtained before and during standard surgery (patients may have had tumor tissue obtained before study entry and stored). Serum samples and tumor tissue are analyzed by immunohistochemistry and western blot. Tumor markers (such as PKA expression) are determined and marker levels are measured in serum samples and tissues.

PROJECTED ACCRUAL: Approximately 30 patients will be accrued for this study.

Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

patients with colorectal cancer

Colorectal Cancer
  • Genetic: western blotting
  • Other: immunohistochemistry staining method
  • Other: laboratory biomarker analysis
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided


  • Diagnosis of colon cancer

    • Metastatic disease for which surgical resection is indicated
    • Metastatic disease accessible for tissue biopsy OR previously biopsied tissue is available


  • Platelet count ≥ 80,000/mm^3
  • INR ≤ 1.3
  • PTT ≤ upper limit of normal
  • No history of bleeding disorders or abnormal clotting factors
  • No extrahepatic biliary obstruction


  • See Disease Characteristics
18 Years and older
Contact information is only displayed when the study is recruiting subjects
United States
CDR0000078662, P30CA051008, GUMC-00074, NCI-G01-1992
John Marshall, MD, Georgetown University
Georgetown University
National Cancer Institute (NCI)
Study Chair: John L. Marshall, MD Lombardi Cancer Research Center
Georgetown University
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP